Conference
Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada
Abstract
Abstract
Introduction: Recombinant Factors VIII Fc (rFVIIIFc) and IX Fc (rFIXFc) fusion proteins are extended half-life (EHL) factor products approved in Canada in 2014 and became available through the Canadian Blood Services in January 2016. Real-world product utilization and clinician practice patterns in EHL prescription are unknown.
Authors
Sun HL; Yang M; Poon M-C; Lee A; Robinson KS; Sholzberg M; Wu JK; Iorio A; Blanchette VS; Klaassen RJ
Volume
132
Publisher
American Society of Hematology
Publication Date
November 29, 2018
DOI
10.1182/blood-2018-99-113858
Conference proceedings
Blood
Issue
Supplement 1
ISSN
0006-4971